Business Model Breakdown
How Innate Pharma SA Makes Money
IPHA
Market Cap
$197M
Annual Revenue
$15M
Profit Margin
0.0%
Employees
174
The Short Version
Innate Pharma is a French biopharmaceutical company that operates as an oncology-focused biotechnology firm. It specializes in discovering, developing, and commercializing novel therapeutic antibodies that leverage the body's natural killer (NK) cells to fight cancer. The company generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical partners, who often take on later-stage clinical development and commercialization in exchange for upfront payments, milestone payments based on development progress, and future royalties on sales of approved drugs. They also receive governmental funding for research.
Where the Revenue Comes From
Collaboration & Licensing Agreements (~31% of FY2025 revenue)
Governmental Funding (~69% of FY2025 revenue)
Who buys: Primarily large pharmaceutical companies for licensing and collaboration, and eventually cancer patients through approved therapies.
Why It Works (Competitive Advantages)
- ✔Proprietary expertise and IP in NK cell-targeting immunotherapies
- ✔Strategic partnership with AstraZeneca for global development of monalizumab
- ✔Diversified oncology pipeline addressing multiple indications
Economic Moat: Narrow (Intangible Assets/IP (proprietary drug candidates and clinical data), Strategic Partnerships (AstraZeneca collaboration provides significant R&D and commercial backing))
What Our Analysis Says
DVR Score as of April 10, 2026
Innate Pharma remains an extremely high-risk, high-reward proposition, with its score unchanged as no material new information has emerged since the previous analysis eight days ago. The core NK cell-targeting pipeline, especially monalizumab partnered with AstraZeneca, offers significant 10x long-term potential in oncology, with major Phase 3 readouts still anticipated in H2 2026. However, the company is battling an immediate and severe financial crisis, highlighted by a 'going concern' warning, cash runway only to end-Q3 2026 (€44.8M as of Dec 31, 2025), and a 55% revenue drop in FY2025. Negative shareholders' equity further underscores the dire situation. While potential catalysts are strong, the investment hinges entirely on securing substantial, likely dilutive, financing and positive clinical data within a very tight timeframe to avoid insolvency.